Ozenoxacin, sold under the brand names Ozanex and Xepi, is a quinolone antibiotic used for the treatment of impetigo. A 1% topical cream is approved for treatment of impetigo in Canada and in the United States. Ozenoxacin is active against some bacteria t + some more technical info It is a nonfluorinated quinolone with potent in vitro activity against common superficial skin pathogens including Staphylococcus aureus and Streptococcus pyogenes and demonstrates activity against strains with certain resistance mechanisms. Pharmacodynamically it targets bacterial type II topoisomerases, producing bactericidal effects at the site of application with minimal systemic absorption when formulated as a 1% topical cream. The drug substance is characterized by chromatographic purity profiling, mass spectrometric identity confirmation and validated potency assays to support consistent topical performance.
Parent: Ozenoxacin
Parent: Ozenoxacin
Parent: Ozenoxacin
The impurity profile for ozenoxacin is defined by process- and degradation-related species that are monitored during drug substance and finished product control. Typical related compounds include demethylated analogues, N-oxide species, oxidative degradants and ring-modified products; manufacturers set acceptance criteria based on ICH principles and regulatory filings. Typical quality control limits used in dossiers and specifications are individual known impurities generally limited to the range 0.1 to 1.0 percent depending on identification and toxicological qualification, with total related substances commonly controlled to not exceed about 2.0 percent. Stability testing uses forced-degradation and real-time studies with validated HPLC methods to quantify each impurity and to ensure limits are met throughout shelf life.
Ozenoxacin cream is approved for impetigo and is intended for superficial bacterial skin infections; it is not routinely indicated for acne vulgaris or typical inflammatory pimples. Occasional off-label topical use may occur under clinician guidance if a bacterial component is suspected, but acne management is usually directed by acne-specific therapies and a healthcare professional should be consulted before using ozenoxacin for pimples.
Both mupirocin and ozenoxacin are topical antibiotics used for skin infections, with mupirocin long established for nasal carriage and impetigo and ozenoxacin recently approved as a 1% cream for impetigo. Comparative effectiveness depends on the infecting organism and local resistance patterns; ozenoxacin has demonstrated activity against many common impetigo pathogens, including some strains with resistance to older agents, while mupirocin remains effective against many Staphylococcus and Streptococcus strains. Choice should be guided by clinical judgement, organism susceptibility when available, and formulary considerations.
Ozenoxacin 1% cream is used topically for the treatment of impetigo caused by susceptible bacteria. It is formulated for localized application to affected skin lesions to reduce bacterial load and resolve superficial infection with low systemic exposure.
Ozenoxacin inhibits bacterial type II topoisomerases, specifically DNA gyrase and topoisomerase IV, interfering with DNA replication and transcription and producing bactericidal activity against susceptible Gram-positive skin pathogens.
